Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children

Most commonly diagnosed cancer pathologies in the pediatric population comprise leukemias and cancers of the nervous system. The percentage of cancer survivors increased from approximatively 50% to 80% thanks to improvements in medical treatments and the introduction of new chemotherapies. However,...

Full description

Saved in:
Bibliographic Details
Main Authors: Luigia Meo (Author), Maria Savarese (Author), Carmen Munno (Author), Peppino Mirabelli (Author), Pia Ragno (Author), Ornella Leone (Author), Mariaevelina Alfieri (Author)
Format: Book
Published: MDPI AG, 2023-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_0cb81a3c6e6e4003b6d7f1f22546b14a
042 |a dc 
100 1 0 |a Luigia Meo  |e author 
700 1 0 |a Maria Savarese  |e author 
700 1 0 |a Carmen Munno  |e author 
700 1 0 |a Peppino Mirabelli  |e author 
700 1 0 |a Pia Ragno  |e author 
700 1 0 |a Ornella Leone  |e author 
700 1 0 |a Mariaevelina Alfieri  |e author 
245 0 0 |a Circulating Biomarkers for Monitoring Chemotherapy-Induced Cardiotoxicity in Children 
260 |b MDPI AG,   |c 2023-11-01T00:00:00Z. 
500 |a 10.3390/pharmaceutics15122712 
500 |a 1999-4923 
520 |a Most commonly diagnosed cancer pathologies in the pediatric population comprise leukemias and cancers of the nervous system. The percentage of cancer survivors increased from approximatively 50% to 80% thanks to improvements in medical treatments and the introduction of new chemotherapies. However, as a consequence, heart disease has become the main cause of death in the children due to the cardiotoxicity induced by chemotherapy treatments. The use of different cardiovascular biomarkers, complementing data obtained from electrocardiogram, echocardiography cardiac imaging, and evaluation of clinical symptoms, is considered a routine in clinical diagnosis, prognosis, risk stratification, and differential diagnosis. Cardiac troponin and natriuretic peptides are the best-validated biomarkers broadly accepted in clinical practice for the diagnosis of acute coronary syndrome and heart failure, although many other biomarkers are used and several potential markers are currently under study and possibly will play a more prominent role in the future. Several studies have shown how the measurement of cardiac troponin (cTn) can be used for the early detection of heart damage in oncological patients treated with potentially cardiotoxic chemotherapeutic drugs. The advent of high sensitive methods (hs-cTnI or hs-cTnT) further improved the effectiveness of risk stratification and monitoring during treatment cycles. 
546 |a EN 
690 |a pediatric cancer 
690 |a children 
690 |a chemotherapy 
690 |a cardiotoxicity 
690 |a troponin 
690 |a high-sensitivity-troponin 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 15, Iss 12, p 2712 (2023) 
787 0 |n https://www.mdpi.com/1999-4923/15/12/2712 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/0cb81a3c6e6e4003b6d7f1f22546b14a  |z Connect to this object online.